Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
November 15, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
Autolus Therapeutics announces participation in upcoming conferences
November 06, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces participation in upcoming conferences
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
November 02, 2023 09:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 02, 2023 07:11 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
September 05, 2023 07:00 ET
|
Autolus Therapeutics plc
Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in...
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
August 03, 2023 07:00 ET
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US...
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
July 19, 2023 07:00 ET
|
Autolus Therapeutics plc
- Veronica Hersberger appointed as Senior Vice President, Medical Affairs- Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program LONDON,...
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
July 18, 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
July 06, 2023 07:00 ET
|
Autolus Therapeutics plc
Long-term CAR T cell persistence is associated with durable responses in B-ALLObe-cel CAR T cells can persist in patients at levels sufficient to allow their isolation from blood samples, even years...
Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
June 20, 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...